G9068 HCPCS Reimbursement & Policy Benchmarks | OpenPayer

Summary & Overview

HCPCS G9068: Limited Disease Status for Small Cell Lung Cancer

HCPCS Level II code G9068 denotes an oncology disease-status classification for small cell and combined small cell/non-small cell lung cancer when the initial extent of disease was limited and there is no evidence of progression, recurrence, or metastases. The code is designated for use within a Medicare-approved demonstration project and supports standardized reporting of disease status in that context. Nationally, a discrete code for this clinical circumstance helps track outcomes, utilization, and program-specific reporting across participating institutions.

Key payers considered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical meaning, the service type and typical sites of service, and which payers are relevant to coverage and reporting. The publication also provides benchmarks and policy context where available, highlights demonstration-project constraints tied to Medicare, and outlines clinical circumstances under which the code applies.

This summary is intended for a national audience of billing professionals, oncology program managers, and policy analysts seeking clarity on code purpose, payer relevance, and what to expect in reporting and administrative use for G9068 within demonstration projects. Data not available in the input will be identified in relevant sections.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9068HCPCS Level IIoncologysmall cell lung cancerdisease statusdemonstration projectoutcomes reportinghospital outpatientoncology clinic

Billing Code Overview

HCPCS Level II code G9068 describes an oncology disease-status classification for small cell and combined small cell/non-small cell lung cancer. The code is specific to cases where the extent of disease was initially established as limited and there is no evidence of disease progression, recurrence, or metastases. Use of this code is limited to a Medicare-approved demonstration project.

Service type: Oncology disease status assessment
Typical site of service: Oncology clinics or hospital outpatient departments where disease-status evaluations are performed as part of cancer care and reporting for demonstration projects

Clinical & Coding Specifications

Clinical Context

A typical patient is a 62-year-old current or former smoker diagnosed with small cell lung cancer (SCLC) or combined small cell/non-small cell lung cancer whose initial staging established limited disease confined to one hemithorax and regional lymph nodes with no evidence of progression, recurrence, or distant metastases. The patient is enrolled in a Medicare-approved demonstration project monitoring disease status after initial therapy (chemotherapy, radiotherapy, or combined modality). Clinical workflow: oncology clinic documents history, physical exam, and review of recent imaging (CT chest, PET-CT) and pathology confirming limited-stage SCLC. Multidisciplinary tumor board documents extent of disease as limited and absence of progression. The oncology clinician completes documentation required for the demonstration project, assigns the billing code G9068 to indicate disease status (limited disease; no progression/recurrence/metastases), and submits claims with appropriate modifiers and provider taxonomy. Typical site of service: outpatient oncology clinic, hospital outpatient department, or cancer center associated with the Medicare demonstration project.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	When no modifier applies to the claim for the service.

HCPCS G8817: Statin Therapy Not Prescribed at Discharge, Reason Not Given

HCPCS-G8491-HIV-AIDS-MEASURES-REPORTING-INTENT

HCPCS G8491: Intent to Report HIV/AIDS Measures

HCPCS-G0454-DME-FACE-TO-FACE-DOCUMENTATION-NP-PA-CNS

HCPCS G0454: Face-to-Face DME Determination Documentation

HCPCS-G0503-PSYCHIATRIC-COLLABORATIVE-CARE-MANAGEMENT-SUBSEQUENT-60-MIN

HCPCS G0503: Subsequent Psychiatric Collaborative Care Management, First 60 Minutes

HCPCS-G9904-MEDICAL-REASON-NO-TOBACCO-SCREENING

HCPCS G9904: Documentation of Medical Reason for Not Screening for Tobacco Use

HCPCS-G9483-REMOTE-IN-HOME-NEW-PATIENT-EVALUATION-TELEHEALTH

HCPCS G9483: Remote In-Home New Patient Evaluation via Telehealth

HCPCS-G2199-PATIENT-NOT-SCREENED-UNHEALTHY-ALCOHOL-USE

HCPCS G2199: Patient Not Screened for Unhealthy Alcohol Use

HCPCS-G2099-OLDER-PATIENTS-FRAILTY-ADVANCED-ILLNESS

HCPCS G2099: Patients 66+ with Frailty and Advanced Illness

HCPCS-G9643-ELECTIVE-SURGERY

HCPCS G9643: Elective Surgery

HCPCS-G9838-METASTATIC-DISEASE-AT-DIAGNOSIS

HCPCS G9838: Patient Has Metastatic Disease at Diagnosis

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
208500000X	Medical Oncology	Primary specialty managing small cell lung cancer diagnosis, staging, and follow-up.
207RH0000X	Radiation Oncology	Specialty involved when radiotherapy contributes to initial treatment and disease-status assessment.
207L00000X	Pulmonary Disease	Pulmonologists often perform diagnostic bronchoscopic staging and interpret imaging.
207K00000X	Hematology/Oncology	Physicians with combined hematology/oncology training managing systemic therapy and status documentation.
363A00000X	General Practice (Oncology Clinic Providers such as advanced practice clinicians)	Advanced practice clinicians who document visits and assist with demonstration project reporting.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Represents primary lung cancer when site specificity is not documented; applicable to small cell presentations.
`C34.11`	Malignant neoplasm of upper lobe, right bronchus or lung	Common anatomic site for lung cancers including small cell; relevant for staging and documenting limited disease.
`C34.12`	Malignant neoplasm of middle lobe, right bronchus or lung	Anatomical localization used in staging and imaging correlation.
`C34.31`	Malignant neoplasm of upper lobe, left bronchus or lung	Site-specific code used in documentation of primary tumor location for staging.
`C34.32`	Malignant neoplasm of middle lobe, left bronchus or lung	Alternative anatomic site relevant to initial disease extent assessment.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Included to represent common metastatic site to exclude when documenting no metastases in limited disease.
`Z08`	Encounter for follow-up examination after completed treatment for malignant neoplasm	Used when documenting surveillance and disease-status assessment after initial therapy in the demonstration project.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`71045`	Radiologic examination, chest; single view, frontal	Baseline or follow-up chest radiograph used in initial staging or to document absence of progression.
`71260`	CT chest with contrast	Cross-sectional imaging commonly used to assess extent of disease, evaluate response, and document no metastases.
`78815`	Positron emission tomography (PET) with concurrently acquired CT for attenuation correction and anatomical localization; whole body	PET-CT is frequently used in staging limited versus extensive SCLC and to confirm no distant metastases.
`31622`	Bronchoscopy, flexible, including simple brushing or washing; with biopsy, single or multiple	Endoscopic biopsy or staging procedure that may be performed during initial workup to establish histology and local extent.
`99499`	Unlisted evaluation and management service	Used rarely for demonstration-specific documentation or reporting elements not captured by standard E/M codes when required by the project.

OpenPayer